Clinical trials: Predictive Cancer Model, active
Thyroid Papillary Carcinoma, Contrast Enhanced Ultrasound
Preoperative Prediction of Lymph Node Metastasis in T1N0M0 Papillary Thyroid Carcinoma by Using Contrast-enhanced Ultrasound
Similarly, the burden of central lymph node metastasis affects the individualized management of patients with T1N0M0 papillary thyroid carcinoma (PTC): lymph node metastasis is a contraindication to thermal ablation; low-burden…
- Trial name
- NCT07357571
- Where
- 2 sites in China
- Volunteers
- 600 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Colorectal Cancer Liver Metastasis
Prospective Validation of an AI Model for Predicting Liver Metastasis in Colorectal Cancer
This is a prospective, multicenter, observational study designed to validate the predictive accuracy of a pre-developed multimodal deep learning model.
- Trial name
- NCT07392567
- Testing
- Multimodal Deep Learning Prediction Model
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Tongji Hospital
Early Gastric Cancer
A Predictive Model Based on Narrow Band Imaging for Early Gastric Cancerous Lesions
Without high diagnostic efficacy of endoscopic forceps biopsy (EFB) and with low diagnostic efficacy of narrow band imaging (NBI) in novice endoscopists and endoscopists of community hospitals in China, it is urgent to improve…
- Trial name
- NCT02968069
- Testing
- NBI
- Volunteers
- 300 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
IBD (Inflammatory Bowel Disease), Colon Cancer
Microbiota: Its Role in Chronic Inflammation, IDB and Risk of Colorectal Cancer. Evaluation of a Predictive Prognostic Model With Therapeutic Implications
The gut microbiome is emerging as a crucial factor in several intestinal diseases, contributing to the etiopathogenesis of inflammatory disorders.
- Trial name
- NCT07106463
- Where
- Italy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Messina
Predictive Cancer Model
Prospective Validation of Liver Cancer Risk Computation (LIRIC) Models
The goal of this prospective observational cohort study is to validate previously developed Hepatocellular Carcinoma (HCC) risk prediction algorithms, the Liver Risk Computation (LIRIC) models, which are based on electronic…
- Trial name
- NCT06140823
- Testing
- Liver Risk Computation Model (LIRIC), Liver Risk Computation Model (LIRIC)_cirrhosis, Liver Risk Computation Model (LIRIC)_no_cirrhosis
- Where
- United States
- Volunteers
- 6,000,000 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Lung Cancer, Solid Pulmonary Nodules
Constructing a Predictive Model for Differentiating Between Benign and Malignant Solid Pulmonary Nodules Based on Clinical and Imaging Features.
Study Objective: To comprehensively analyze the preoperative clinical and imaging characteristics of solid pulmonary nodules, investigate the risk factors associated with malignant solid pulmonary nodules, and provide a reference…
- Conditions
- Lung Cancer, Solid Pulmonary Nodules, Pulmonary Nodules
- Trial name
- NCT06685458
- Testing
- Preoperative Clinical and Imaging Feature Evaluation for Predictive Modeling
- Volunteers
- 320 people
- Sponsor
- The Third Affiliated Hospital of Kunming Medical College.
Gastric Cancer, Adenocarcinoma of the Stomach
Radiomics and Molecular Expression Predictive Model for Esophago-Gastric Junction and Gastric Cancer TRG
The aim of this study is to develop a CT scan-based radiomics predictive model about tumor regression grade (TRG) in patients with esophago-gastric junction (EGJ) ang gastric cancer undergoing perioperative chemotherapy.
- Trial name
- NCT04878783
- Testing
- CT scan
- Where
- 5 sites in Italy, Netherlands
- Volunteers
- 138 people
- Sponsor
- University of Roma La Sapienza
Gastric Cancer, Immunotherapy
The Construction of a Predictive Model for Gastric Cancer Immunotherapy Response Based on Tumor-Infiltrating Lymphocytes (TILs) and Histone H3K4me3 in the Tumor Microenvironment
Gastric cancer is one of the cancers with a high mortality rate globally, and its treatment outcomes urgently need to be improved.
- Trial name
- NCT07069842
- Testing
- Multiplex Immunofluorescence Technology, Co-Immunoprecipitation (Co-IP) Technology, Immunohistochemistry
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Changzhi People's Hospital Affiliated to Changzhi Medical College
Prognostic Cancer Model
Prognostic Significance of ctDNA in HL
Specific somatic mutations using ctDNA will be analyzed in predefined subgroups of cHL (e.g., age <60 and ≥ 60 years, EBV). These mutations will be correlated with response to the treatment in the first line, in the relapse…
- Trial name
- NCT06263530
- Where
- 5 sites in Czechia
- Volunteers
- 500 people
- Sponsor
- Interni hematologicka klinika FNKV
Pancreatic Ductal Adenocarcinoma
Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer
This study aims to develop and validate a predictive microRNA (miRNA) panel to assess the response to neoadjuvant chemotherapy (NACT) in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC).
- Trial name
- PRECEPT (NCT07226154)
- Testing
- Small RNA sequencing, PRECEPT assay (qRT-PCR validation)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- City of Hope Medical Center
Prostate Cancer, Risk Assessment
PROstate Cancer Risk Calculator for ACTionable Clinical Decision-making in Nigeria
This study is a pilot trial that builds on findings from the validation of prostate cancer risk calculators in Nigerian men. The goal of the overall study is to improve the early detection of prostate cancer in a high-risk…
- Conditions
- Prostate Cancer, Risk Assessment, Clinical Decision Support Systems, Predictive Value of Tests
- Trial name
- PROACT (NCT07733440)
- Testing
- (a) Training and (b) Supported risk assessment
- Where
- Nigeria
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Ahmadu Bello University
Pancreatic Cancer
A Study on a Predictive Model for Efficacy and Prognosis of Pancreatic Carcinoma Based on Multimodal Data
The goal of this observational study is to learn if combining information from CT scans, blood tests, and pathology reports can better predict how pancreatic cancer will progress.
- Trial name
- NCT07561814
- Where
- China
- Volunteers
- 1,030 people
- Sponsor
- Shanghai Zhongshan Hospital
Breast Cancer, Estrogen Receptor-Positive
Validity of Brain Metastasis Risk Predictive Model in Hormone Positive Breast Cancer Patients
This study aims to validate a prediction model of brain metastasis risk for females with HR+ breast cancer by using variables collected at diagnosis.
- Trial name
- NCT06729099
- Volunteers
- 128 people
- Sponsor
- Assiut University
Phyllodes Breast Tumor, Artificial Intelligence
AI-Assisted System for Accurate Diagnosis and Prognosis of Breast Phyllodes Tumors
Breast phyllodes tumor (PT) is a rare fibroepithelial tumor, accounting for 1% to 3% of all breast tumors, categorized by the WHO into benign, borderline, and malignant, based on histopathology features such as tumor border…
- Conditions
- Phyllodes Breast Tumor, Artificial Intelligence, Multiomics, Prognostic Cancer Model
- Trial name
- NCT06286267
- Testing
- imaging
- Where
- 4 sites in China
- Volunteers
- 4,000 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Glioma
The Predictive Value of MRI for Adult-type Diffuse Gliomas
The goal of this observational study is to learn about the diagnostic value of preoperative MRI examination for adult-type diffuse gliomas.
- Trial name
- MRI; glioma; (NCT06572592)
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Breast Cancer, Perimenopause
AMH Dynamic Changes to Predict Ovarian Reserve in Perimenopausal Breast Cancer
This study is a prospective observational cohort study aimed at developing a clinical model based on dynamic changes in anti-Müllerian hormone (AMH) to predict ovarian reserve in perimenopausal women with hormone…
- Conditions
- Breast Cancer, Perimenopause, Ovarian Reserve
- Trial name
- NCT07497191
- Volunteers
- 300 people
- Sponsor
- Shengjing Hospital
Cervical Cancer Treated with Pelvic Radiotherapy, Cervical Cancers
Establishment and Validation of Prediction Model of Simultaneous Chemoradiotherapy for Cervical Cancer Organoids
This is a single-arm, single-center, open-label, Phase II study aimed at assessing the efficacy of organoids in predicting the response to radiotherapy and chemotherapy in cervical cancer
- Trial name
- ECCO (NCT06786780)
- Testing
- Drug: Cisplatin
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Chongqing University Cancer Hospital
Glioblastoma, Organoid
Drug Response Testing and Repurposing Using Glioblastoma Organoid
The aim of this observational study, based on a prospectively collected cohort, is to evaluate the prognostic value of patient-derived organoids in predicting responses to conventional and repurposing drugs, including…
- Trial name
- NCT06782984
- Testing
- Organoid-based drug sensitivity test
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Chungnam National University Hospital
Paraganglioma, Pheochromocytoma
Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study
Phaeochromocytomas and paragangliomas (PPGLs) are tumours of the adrenal medulla and extra-adrenal sympathetic nervous system, some which can become metastatic. It is a very rare disease and the tumours are often detected late.
- Conditions
- Paraganglioma, Pheochromocytoma, Genetic Predisposition to Disease, Pathology
- Trial name
- PPGL-Pred (NCT04788927)
- Where
- 2 sites in Denmark
- Volunteers
- 400 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Pancreatic Adenocarcinoma, Predictive Cancer Model
Prospective Validation of an EHR-based Pancreatic Cancer Risk Model
The goal of this prospective observational cohort study is to validate a previously developed pancreatic cancer risk prediction algorith (the PRISM model) using electronic health records from the general population.
- Trial name
- NCT05973331
- Testing
- Pancreatic Cancer Risk Model (PRISM)
- Where
- United States
- Volunteers
- 6,134,060 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center